Literature DB >> 1749290

The evolution of Hodgkin's disease and necrobiotic xanthogranuloma syndrome.

C B Reeder1, S M Connolly, R K Winkelmann.   

Abstract

We describe a woman in whom hypogammaglobulinemia and severe granulomatous cutaneous lesions had developed during childhood; subsequently, Hodgkin's disease and necrobiotic xanthogranuloma were diagnosed. This case illustrates an apparent association with disease activity and raises the question of a direct relationship of necrobiotic xanthogranuloma with lymphoproliferative disease.

Entities:  

Mesh:

Year:  1991        PMID: 1749290     DOI: 10.1016/s0025-6196(12)62473-2

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  4 in total

Review 1.  Adult xanthogranulomatous disease of the orbit and ocular adnexa: new immunohistochemical findings and clinical review.

Authors:  J A Sivak-Callcott; J Rootman; S L Rasmussen; R A Nugent; V A White; D Paridaens; Z Currie; G Rose; B Clark; A A McNab; F V Buffam; J M Neigel; M Kazim
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

2.  A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria.

Authors:  Caroline A Nelson; Connie S Zhong; David A Hashemi; Hovik J Ashchyan; Zoe Brown-Joel; Megan H Noe; Sotonye Imadojemu; Robert G Micheletti; Ruth Ann Vleugels; Karolyn A Wanat; Misha Rosenbach; Arash Mostaghimi
Journal:  JAMA Dermatol       Date:  2020-03-01       Impact factor: 10.282

3.  Spectacular skin nodules: cutaneous necrobiotic xanthogranuloma without paraproteinemia.

Authors:  Shimoni Kadakia; Nitin Nadkarni; Sham Sonavane; Sunil Ghate
Journal:  Indian J Dermatol       Date:  2012-09       Impact factor: 1.494

Review 4.  Systemic therapy of necrobiotic xanthogranuloma: a systematic review.

Authors:  Lisa Steinhelfer; Thomas Kühnel; Herbert Jägle; Stephanie Mayer; Sigrid Karrer; Frank Haubner; Stephan Schreml
Journal:  Orphanet J Rare Dis       Date:  2022-03-24       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.